ストックスクリーナーアプリを入手
0.786
2.21%
0.017
前日終値:
$0.769
開ける：
$0.7637
24時間の取引高:
40,433
Relative Volume:
0.23
時価総額：
$5.09M
収益：
-
当期純損益:
$-6.07M
株価収益率:
-0.136
EPS:
-5.78
ネットキャッシュフロー:
$-7.34M
1週間 パフォーマンス:
+6.04%
1か月 パフォーマンス:
-19.18%
6か月 パフォーマンス:
-19.80%
1年 パフォーマンス:
-16.38%
1日の値動き範囲:
$0.761
$0.79
1週間の範囲:
$0.7501
$0.85
52週間の値動き範囲:
$0.7151
$4.1699
Adial Pharmaceuticals Inc Stock (ADIL) Company Profile
名前
Adial Pharmaceuticals Inc
セクター
電話
434-422-9800
住所
1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA
ADIL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ADIL
Adial Pharmaceuticals Inc
|
0.786 | 5.09M | 0 | -6.07M | -7.34M | -5.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Adial Pharmaceuticals Inc Stock (ADIL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-14 | 開始されました | Rodman & Renshaw | Buy |
| 2018-10-30 | 開始されました | Maxim Group | Buy |
| 2018-10-11 | 開始されました | Dawson James | Buy |
Adial Pharmaceuticals Inc (ADIL) 最新ニュース
Adial Pharmaceuticals' Chief Medical Officer Presents AD04 at the Scientific Federation 7th World Congress on Nursing & Healthcare - ACCESS Newswire
Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD(TM) Pivotal Phase 3 Trial in Sweden and Estonia - ACCESS Newswire
Adial Pharmaceuticals Granted New U.S. Patent Expanding - GlobeNewswire
Adial Pharmaceuticals Granted New U.S. Patent On Method To Identify Genetic Markers In Alcohol or Opioid-Related Disorders - Marketscreener.com
Adial Granted New U.S. Patent Expanding Genetic-Based Approach For Addiction Treatment - Nasdaq
Adial Pharmaceuticals secures patent for genetic addiction treatment - Investing.com
This Groundbreaking Patent Could Transform How We Treat AddictionHere's Why Genetics Matter - StockTitan
Adial Pharmaceuticals Receives Approval to Commence Phase 3 Trial in Bulgaria - ACCESS Newswire
Adial Is Filling The Gap In Alcohol Use Disorder Treatment With Repurposed Drug - News & Insights
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Sees Significant Growth in Short Interest - Defense World
Adial Pharmaceuticals Awarded U.S. Patent For Genotype-Specific Treatment Of Opioid Disorders - Nasdaq
Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders - The Manila Times
Adial Pharmaceuticals Secures Patent for Genetically Targeted Treatment Methods in Addiction Therapy - Nasdaq
Adial Pharmaceuticals secures new patent for addiction treatment - Investing.com
Revolutionary Patent Win: Adial's DNA-Guided Solution Takes On $35B Addiction Crisis - StockTitan
EXCLUSIVE: Adial Pharmaceuticals Secures New US Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders - Yahoo Finance
Reddit (RDDT) Q4 Earnings: What To Expect - The Globe and Mail
Adial Pharmaceuticals Schedules Business Update Conference Call to Discuss Planned Acquisition of Purnovate and other Recent Developments - ACCESS Newswire
Adial Pharmaceuticals Submits Clinical Trial Applications in Six Additional European Countries - ACCESS Newswire
Clinical Trials News Live Feed - StockTitan
Adial completes key study for alcohol disorder drug - MSN
Adial Pharmaceuticals Receives European Medicines Agency (EMA) Agreement on the Pediatric Investigation Plan (PIP) for AD04 in Alcohol Use Disorder - ACCESS Newswire
ADILAdial Pharmaceuticals, Inc Latest Stock News & Market Updates - StockTitan
Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder - The Manila Times
Adial completes key study for alcohol disorder drug By Investing.com - Investing.com UK
Adial Pharmaceuticals Announces Positive Clinical Study - GlobeNewswire
Game-Changing Alcohol Addiction Treatment Clears Critical FDA Hurdle - StockTitan
EXCLUSIVE: Adial Pharmaceuticals Reveals Positive Pharmacokinetics Study Results Of AD04 For Alcohol Use Disorder - Benzinga
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Down 60.8% in January - Defense World
Adial Pharma stock hits 52-week low at $0.72 amid market challenges - Investing.com Nigeria
Adial Pharmaceuticals Announces Appointment of Alex Lugovoy as Head of Strategy - ACCESS Newswire
Why Bitcoin-Linked MicroStrategy Along With Adial Pharmaceuticals, Alpine Immune Sciences, Marin Software, And Tesla Are On Investors' Radars Today - MSN
Adial Pharmaceuticals to Commence Business Development Meetings - Defense World
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update - Defense World
Adial Pharmaceuticals Focuses on Strategic Growth Initiatives - TipRanks
Adial Pharmaceuticals Highlights AD04 for Alcohol Use Disorder - TipRanks
Alcohol Use Disorder Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Therapies, Treatment, Companies by DelveInsight - Barchart
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Up 16.4% in December - Defense World
Adial Pharmaceuticals (NASDAQ:ADIL) Stock Quotes, Forecast and News Summary - Benzinga
Adial Pharmaceuticals’ New Purchase Agreement with Alumni Capital - TipRanks
Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Drops By 71.7% - Defense World
Alcohol Use Disorder Market Set for Remarkable Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.
Adial Pharmaceuticals revises CEO's compensation package By Investing.com - Investing.com South Africa
Adial Pharmaceuticals revises CEO's compensation package - Investing.com India
Adial Pharmaceuticals Inc (ADIL) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):